^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR T790M + HER-2 amplification

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor, ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
    Entrez ID:
    1956; 2064
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over2years
    Acquired concurrent EGFR T790M and driver gene resistance from EGFR-TKIs hampered osimertinib efficacy in advanced lung adenocarcinoma (ELCC 2022)
    One patient had acquired EGFR T790M, STRN-ALK fusion, and EGFR amplification after gefitinib progression and was shortly resistant to osimertinib with MET amplification. The other patient developed to acquired EGFR T790M and MET amplification post-dacomitinib and acquired CCDC6-RET fusion after 4-month osimertinib treatment...The T790M accompanying diver gene resistance will be a new subtype after EGFR-TKIs progression and needs effective treatment options. Legal entity responsible for the study The authors.
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • CCDC6 (Coiled-Coil Domain Containing 6) • STRN (Striatin)
    |
    EGFR mutation • HER-2 amplification • MET amplification • EGFR T790M • RET fusion • EGFR amplification • ALK fusion • CCDC6-RET fusion • KRAS G12 • KRAS amplification • STRN-ALK fusion • ALK amplification • EGFR T790M + HER-2 amplification • EGFR T790M + MET amplification
    |
    Tagrisso (osimertinib) • gefitinib • Vizimpro (dacomitinib)